

## **Specialty Pharmacy Program**

### **Boniva Injection (ibandronate sodium)**

#### **DESCRIPTION**

Boniva Injection is an intravenously-administered bisphosphonate that is indicated for the treatment of postmenopausal osteoporosis.

#### **APPROVAL DURATION**

Approval duration: lifetime

#### **APPROVAL CRITERIA**

Boniva Injection will be approved if the patient meets the following criteria:

- I. Patient is a woman with a diagnosis of postmenopausal osteoporosis **AND**
- II. Patient does not have uncorrected hypocalcemia **AND**
- III. Patient's vitamin D status has been evaluated and corrected **AND**
- IV. Patient will receive adequate intake of supplemental calcium and vitamin D **AND**
- V. Patient does not have severe renal impairment (eg, CrCl <30 mL/min or SCr >2.3 mg/dL) **AND**
- VI. Patient will have serum creatinine measured prior to each dose **AND**
- VII. Patient is intolerant of at least 2 oral bisphosphonates (e.g., Actonel, Fosamax, or Boniva tablets) **OR**
- VII. Patient has a history of severe malabsorption making the use of oral bisphosphonates ineffective **OR**
- VIII. Patient has a diagnosis of esophageal stricture, achalasia, or other severe esophageal dysmotility disorder **OR**
- IX. The patient is unable to stand or sit upright for 60 minutes.